‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer 08 Sep 2023 A new radioactive medicine that seeks out tumour cells to deliver a targeted dose of radiation greatly improves quality of life for patients with advanced prostate cancer, a phase III study finds. Find out more Show/Hide
ICR welcomes MHRA approval of 'search and destroy' prostate cancer treatment 11 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer. Find out more Show/Hide
ICR welcomes FDA approval of ‘search and destroy’ treatment 25 Mar 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a potent radioactive medicine that searches for tumour cells to deliver a radioactive payload, has been approved by the US Food and Drug Administration (FDA) for treating some advanced prostate cancers. Find out more Show/Hide
Gene test picks out prostate cancers patients who could benefit from ‘search-and-destroy’ medicine 23 Jul 2019